1046079-35-9

Basic information

• Product Name: 5-(Piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one hydrochloride
• Synonyms: 5-(Piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one hydrochloride
• CAS NO: 1046079-35-9
• Molecular Formula: C7H12ClN3O2
• Molecular Weight: 205.64208
• Mol File: 1046079-35-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 5-(Piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(Piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one hydrochloride(1046079-35-9)
• EPA Substance Registry System: 5-(Piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one hydrochloride(1046079-35-9)

Safety Data

• Hazardous Substances Data: 1046079-35-9(Hazardous Substances Data)

Usage

General Description

5-(Piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one hydrochloride is a chemical compound that belongs to the family of oxadiazole derivatives. It is a synthetic compound with potential pharmacological uses, including potential antipsychotic and anxiolytic effects. The compound is a hydrochloride salt, meaning it is a positively charged ion paired with a negatively charged chloride ion. 5-(Piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one hydrochloride may have potential as a drug candidate for the treatment of various neurological disorders, but further studies and research are needed to fully understand its biological activity and potential therapeutic uses.

Upstream product

• 1004527-94-9 4-(5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis of GABAA receptor agonists and evaluation of their α-subunit selectivity and orientation in the GABA binding site

Drugs used to treat various disorders target GABAA receptors. To develop α subunit selective compounds, we synthesized 5-(4-piperidyl)-3-isoxazolol (4-PIOL) derivatives. The 3-isoxazolol moiety was substituted by 1,3,5-oxadiazol-2-one, 1,3,5-oxadiazol-2-thione, and substituted 1,2,4-triazol-3-ol heterocycles with modifications to the basic piperidine substituent as well as substituents without basic nitrogen. Compounds were screened by [3H]muscimol binding and in patch-clamp experiments with heterologously expressed GABAA αiβ 3γ2 receptors (i = 1-6). The effects of 5-aminomethyl-3H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all α subunit isoforms. 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at α2-, α3-, and α5-containing receptors. When coapplied with GABA, they were antagonistic in α2-, α4-, and α6-containing receptors and potentiated α3-containing receptors. 6a protected GABA binding site cysteine-substitution mutants α1F64C and α1S68C from reacting with methanethiosulfonate-ethylsulfonate. 6a specifically covalently modified the α1R66C thiol, in the GABA binding site, through its oxadiazolethione sulfur. These results demonstrate the feasibility of synthesizing α subtype selective GABA mimetic drugs.